Review




Structured Review

Sequenom mass spectrometer
Mass Spectrometer, supplied by Sequenom, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+detection/mass+spectrometry/pm24613481-61-11-13
Average 86 stars, based on 1 article reviews
mass spectrometer - by Bioz Stars, 2026-11
86/100 stars

Images

Related Articles

Mass Spectrometry:

Article Title: Interaction between HTR2A rs3125 and negative life events in suicide attempts among patients with major depressive disorder: a cross-sectional study
Article Snippet: .. Eight tagSNPs (rs1328683, rs17068986, and rs3125 in HTR2A and rs1123425, rs2682826, rs3741476, rs527590, and rs7959232 in NOS1 ) were detected using Sequenom mass spectrometry (see Additional file ). ..

Article Title: Choosing sweeteners wisely—nutrigenetic study on childhood obesity
Article Snippet: .. Genotyping validation was performed using Sequenom iPLEX matrix-assisted laser desorption/ionization-time of flight mass spectrometry at the National Center for Genome Medicine. ..

Article Title: Interaction between HTR2A rs3125 and negative life events in suicide attempts among patients with major depressive disorder: a cross-sectional study
Article Snippet: .. Sequenom mass spectrometry was used to detect eight tag-single nucleotide polymorphisms (tagSNPs) in HTR2A (rs1328683, rs17068986, and rs3125) and NOS1 (rs1123425, rs2682826, rs3741476, rs527590, and rs7959232). ..

Article Title: Choosing sweeteners wisely-nutrigenetic study on childhood obesity.
Article Snippet: .. Genotyping validation was performed using Sequenom iPLEX matrix-assisted laser desorption/ionization-time of flight mass spectrometry at the National Center for Genome Medicine. ..

Article Title: Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies.
Article Snippet: A small proportion of nonsmall-cell lung cancers (NSCLCs) are associated with mutations in the ERBB2 gene.. We studied the effects of neratinib monotherapy and in combination on 60 patients with ERBB2-mutant NSCLC in the PUMA-NER-4201 study and 78 patients in the SUMMIT study.. Response rates were low with single-agent neratinib and combinations containing temsirolimus or trastuzumab were not markedly better.

Biomarker Discovery:

Article Title: Choosing sweeteners wisely—nutrigenetic study on childhood obesity
Article Snippet: .. Genotyping validation was performed using Sequenom iPLEX matrix-assisted laser desorption/ionization-time of flight mass spectrometry at the National Center for Genome Medicine. ..

Article Title: Choosing sweeteners wisely-nutrigenetic study on childhood obesity.
Article Snippet: .. Genotyping validation was performed using Sequenom iPLEX matrix-assisted laser desorption/ionization-time of flight mass spectrometry at the National Center for Genome Medicine. ..

other:

Article Title: A Functional Variant rs2122031 in ATG7 Is Associated with the Risk of Radiation Pneumonitis
Article Snippet: The alleles were discriminated by mass spectrometry (Sequenom).

Article Title: Methods of identifying and treating patients with HIF-2 inhibitor resistance
Article Snippet: Extension products can then be analyzed by, for example, mass spectrometry, which can distinguish different bases according to their mass-to-charge (m/z) ratio (Sequenom Mass Spectrometry system) or by capillary electrophoresis, which distinguishes bases by size and by the color of fluorescently labeled nucleotides (Applied Biosystems SNaPshot system).

Next-Generation Sequencing:

Article Title: Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies.
Article Snippet: A small proportion of nonsmall-cell lung cancers (NSCLCs) are associated with mutations in the ERBB2 gene.. We studied the effects of neratinib monotherapy and in combination on 60 patients with ERBB2-mutant NSCLC in the PUMA-NER-4201 study and 78 patients in the SUMMIT study.. Response rates were low with single-agent neratinib and combinations containing temsirolimus or trastuzumab were not markedly better.

Sequencing:

Article Title: Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies.
Article Snippet: A small proportion of nonsmall-cell lung cancers (NSCLCs) are associated with mutations in the ERBB2 gene.. We studied the effects of neratinib monotherapy and in combination on 60 patients with ERBB2-mutant NSCLC in the PUMA-NER-4201 study and 78 patients in the SUMMIT study.. Response rates were low with single-agent neratinib and combinations containing temsirolimus or trastuzumab were not markedly better.



Similar Products

90
agena bioscience massarray detection platform
Massarray Detection Platform, supplied by agena bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+detection/massarray+platform/pmc09910734-173-0-3
Average 90 stars, based on 1 article reviews
massarray detection platform - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
agena bioscience kit for the qualitative detection of sars-cov-2 using rt-pcr reaction together with the massarray system
Kit For The Qualitative Detection Of Sars Cov 2 Using Rt Pcr Reaction Together With The Massarray System, supplied by agena bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+detection/massarray+sars+cov+2+panel/pm36747014-37-9-18
Average 90 stars, based on 1 article reviews
kit for the qualitative detection of sars-cov-2 using rt-pcr reaction together with the massarray system - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
agena bioscience commercial kit for the qualitative detection of sars-cov-2 using rt-pcr reaction together with the massarray system
Comparison of SARS-CoV-2 variant identification using Next Generation Sequencing (NGS) and MassARRY PMA-ABDO and PMA-Omicron (n = 358).
Commercial Kit For The Qualitative Detection Of Sars Cov 2 Using Rt Pcr Reaction Together With The Massarray System, supplied by agena bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+detection/massarray+sars+cov+2+panel/pmc09900542-103-9-18
Average 90 stars, based on 1 article reviews
commercial kit for the qualitative detection of sars-cov-2 using rt-pcr reaction together with the massarray system - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Sequenom iplex® gold massarray maldi-tof ms detection
Comparison of SARS-CoV-2 variant identification using Next Generation Sequencing (NGS) and MassARRY PMA-ABDO and PMA-Omicron (n = 358).
Iplex® Gold Massarray Maldi Tof Ms Detection, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+detection/maldi+tof+mass+spectrometry+iplex+platform/pmc04299921-50-6-5
Average 90 stars, based on 1 article reviews
iplex® gold massarray maldi-tof ms detection - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

96
agena bioscience agena massarray methylation detection
Comparison of SARS-CoV-2 variant identification using Next Generation Sequencing (NGS) and MassARRY PMA-ABDO and PMA-Omicron (n = 358).
Agena Massarray Methylation Detection, supplied by agena bioscience, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+detection/Methylation/ppr0552502-125-0-0
Average 96 stars, based on 1 article reviews
agena massarray methylation detection - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

90
Sequenom massarray methylation detection
A A negative correlation between ZNF334 <t>methylation</t> level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
Massarray Methylation Detection, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+detection/massarray+quantitative+methylation+analysis/pmc09085879-231-0-4
Average 90 stars, based on 1 article reviews
massarray methylation detection - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Sequenom massarray sequenom detection
A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
Massarray Sequenom Detection, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+detection/sequenom+massarray/pmc09085879-184-7-8
Average 90 stars, based on 1 article reviews
massarray sequenom detection - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
agena bioscience massarray dna mass spectrometry detection
A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
Massarray Dna Mass Spectrometry Detection, supplied by agena bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+detection/massarray+mass+spectrometer/pm34260825-63-8-13
Average 90 stars, based on 1 article reviews
massarray dna mass spectrometry detection - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Sequenom massarray snp detection
A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
Massarray Snp Detection, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+detection/sequenom+massarray/pmc08787141-153-1-0
Average 90 stars, based on 1 article reviews
massarray snp detection - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Comparison of SARS-CoV-2 variant identification using Next Generation Sequencing (NGS) and MassARRY PMA-ABDO and PMA-Omicron (n = 358).

Journal: Scientific Reports

Article Title: Simultaneous detection of omicron and other SARS-CoV-2 variants by multiplex PCR MassARRAY technology

doi: 10.1038/s41598-023-28715-9

Figure Lengend Snippet: Comparison of SARS-CoV-2 variant identification using Next Generation Sequencing (NGS) and MassARRY PMA-ABDO and PMA-Omicron (n = 358).

Article Snippet: Recently, the commercial kit for the qualitative detection of SARS-CoV-2 using RT-PCR reaction together with the MassARRAY system (Agena Bioscience ® , San Diego, CA, USA) has been developed, and it showed superiority over Real-time PCR assay .

Techniques: Comparison, Variant Assay, Next-Generation Sequencing

A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the MassARRAY methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.

Journal: Cell Death & Disease

Article Title: DNA hypermethylation modification promotes the development of hepatocellular carcinoma by depressing the tumor suppressor gene ZNF334

doi: 10.1038/s41419-022-04895-6

Figure Lengend Snippet: A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the MassARRAY methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.

Article Snippet: MassARRAY methylation detection technology (Sequenom, USA) performed by CapitalBio Technology (Shanghai, China) was used to detect the methylation level of ZNF334 promoter (human) in carcinoma and paracancerous tissues of 25 HCC patients and Zfp334 promoter (mice) in treatment and control group.

Techniques: Methylation, Expressing, Western Blot, Mass Spectrometry, Sequencing

A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the MassARRAY methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.

Journal: Cell Death & Disease

Article Title: DNA hypermethylation modification promotes the development of hepatocellular carcinoma by depressing the tumor suppressor gene ZNF334

doi: 10.1038/s41419-022-04895-6

Figure Lengend Snippet: A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the MassARRAY methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.

Article Snippet: And meanwhile, in clinical samples, we used MassArray Sequenom detection to further verify the DNA methylation changes of ZNF334 promoter in cancerous tissues and adjacent tissues.

Techniques: Methylation, Expressing, Western Blot, Mass Spectrometry, Sequencing